SCHEMBL2524923

SCHEMBL2524923

CC1(C)Oc2ccc(Nc3nc(Nc4ccc(N5CCC(F)(F)CC5)cc4)ncc3F)nc2NC1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.62
FLT3 P36888 4/20 0.62
BTK Q06187 3/20 0.62
AURKA O14965 3/20 0.62
AURKB Q96GD4 3/20 0.62
ADORA3 P0DMS8 2/20 0.62
TYRO3 Q06418 2/20 0.62
PDGFRB P09619 2/20 0.62
PDGFRA P16234 2/20 0.62
EGFR P00533 2/20 0.62
ALK Q9UM73 2/20 0.62
LRRK2 Q5S007 2/20 0.62
PLK4 O00444 2/20 0.62
STK16 O75716 2/20 0.62
RET P07949 2/20 0.62
MAPK8 P45983 2/20 0.62
MAPK9 P45984 2/20 0.62
MST1R Q04912 2/20 0.62
PTK2 Q05397 2/20 0.62
TNK1 Q13470 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2526079 0.92 SYK (0.64) SYKFLT3BTKAURKAAURKB
SCHEMBL2525992 0.92 SYK (0.64) SYKFLT3BTKAURKAAURKB
SCHEMBL2521971 0.91 SYK (0.60) SYKFLT3BTKAURKAAURKB
SCHEMBL2524410 0.91 SYK (0.63) SYKFLT3BTKAURKAAURKB
SCHEMBL2523825 0.90 SYK (0.62) SYKFLT3BTKAURKAAURKB
SCHEMBL2516431 0.90 SYK (0.62) SYKFLT3BTKAURKAAURKB
SCHEMBL2527666 0.90 SYK (0.61) SYKFLT3BTKAURKAAURKB
SCHEMBL2521050 0.89 SYK (0.57) SYKFLT3BTKAURKAAURKB
SCHEMBL2522461 0.89 SYK (0.57) SYKFLT3BTKAURKAAURKB
SCHEMBL2527669 0.89 SYK (0.60) SYKFLT3BTKAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 US claimed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US claimed
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 EP disclosed
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 EP disclosed
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES TYMP, DPYD, TYMS SYK 1871/4885FLT3 183/4885BTK 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.